Download Image
    
Share
  
Post
Cytokine Adsorption for COVID-19
2 studies with 83 patients
Hospital Icon Control
Hospital Icon Cytokine Adsorption Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Cytokine Adsorption studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -72% Mortality -72% RCTs -72% RCT mortality -72% Late -72% Favorscytokine adsorption Favorscontrol
Feb 9
2022
 Stockmann et al., Critical Care Medicine, doi:10.1097/CCM.0000000000005493 CytoSorb Rescue for COVID-19 Patients With Vasoplegic Shock and Multiple Organ Failure: A Prospective, Open-Label, Randomized Controlled Pilot Study
9% lower mortality (p=0.79). RCT 49 COVID-19 patients with vasoplegic shock and multiple organ failure showing no significant difference in shock resolution or mortality with CytoSorb extracorporeal cytokine adsorption compared to standard care.
Jul 31
2021
 Supady et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00177-6 Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial
250% higher mortality (p=0.002). RCT 34 severe COVID-19 patients requiring extracorporeal membrane oxygenation (ECMO) showing significantly higher mortality with cytokine adsorption therapy.